Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.71 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | HTR7 | P34969 | 1/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | GLS | O94925 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7407102 | 0.91 | ACHE (0.78) | ACHEHTR1AHTR7HRH1DRD3 | |
| SCHEMBL21609732 | 0.90 | ACHE (0.59) | ACHEHTR1AHTR7HRH1DRD3 | |
| SCHEMBL21609729 | 0.90 | ACHE (0.59) | ACHEHTR1AHTR7HRH1DRD3 | |
| SCHEMBL17117470 | 0.90 | ACHE (0.59) | ACHEHTR1AHTR7HRH1DRD3 | |
| SCHEMBL29671486 | 0.89 | ACHE (0.58) | ACHEHTR1AHTR7HRH1DRD3 | |
| SCHEMBL28702049 | 0.89 | ACHE (0.58) | ACHEHTR1AHTR7HRH1DRD3 | |
| SCHEMBL14450985 | 0.89 | ACHE (0.57) | ACHEHTR1AHTR7HRH1DRD3 | |
| SCHEMBL29263737 | 0.87 | HPGD (0.59) | ACHEHTR1AHTR7HRH1DRD3 | |
| Methyl Alcohol SCHEMBL28751304 | 0.86 | ACHE (0.77) | ACHEGLS | |
| SCHEMBL6789650 | 0.85 | ACHE (0.69) | ACHEHTR1AHTR7HRH1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814366-B2 | Antiviral compounds and use thereof | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2023-11-14 | — | — | US | disclosed |
| US-11814366-B2 | Antiviral compounds and use thereof | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2023-11-14 | — | — | US | disclosed |
| US-11814366-B2 | Antiviral compounds and use thereof | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2023-11-14 | — | — | US | disclosed |
| EP-3765454-B1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | UNIV DEGLI STUDI DI SIENA (IT) | 2023-11-08 | — | — | EP | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20210070737-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | UNIVERSITA DEGLE STUDI DI SIENA (IT) | 2021-03-11 | — | — | US | disclosed |
| US-20210070737-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | UNIVERSITA DEGLE STUDI DI SIENA (IT) | 2021-03-11 | — | — | US | disclosed |
| EP-3765454-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | Universita' Degli Studi di Siena (IT) | 2021-01-20 | — | — | EP | disclosed |
| WO-2019175436-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | UNIVERSITÀ DEGLI STUDI DI SIENA (IT) | 2019-09-19 | — | — | WO | disclosed |
| WO-2019175436-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | UNIVERSITÀ DEGLI STUDI DI SIENA (IT) | 2019-09-19 | — | — | WO | disclosed |
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-02-19 | — | — | US | disclosed |
| EP-1993536-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20070249599-A1 | Novel Chemical Compounds | DUFFY KEVIN J | 2007-10-25 | — | — | US | disclosed |
| WO-2007103755-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814366-B2 | Antiviral compounds and use thereof | MAVS, EIF2AK2, SARS1 | ACHE 2266/4885HTR1A 4367/4885HTR7 4000/4885 |
| US-20070249599-A1 | Novel Chemical Compounds | HIPK3, HIPK1, HIPK4 | ACHE 4530/4885HTR1A 4211/4885HTR7 3993/4885 |
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | PIK3CA, BTK, PI4KA | ACHE 1064/4885HTR1A 2502/4885HTR7 1993/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | ACHE 2876/4885HTR1A 4764/4885HTR7 4520/4885 |
| US-20210070737-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MAVS, EIF2AK2, SARS1 | ACHE 2266/4885HTR1A 4367/4885HTR7 4000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.